Drug firm, Wockhardt has reported a net profit of Rs 53.80 crore for the second quarter ended September 30, 2011. It had posted a net loss of Rs 67.86 crore for the same quarter last fiscal. The company’s total income has increased by 33.63% at Rs 640.73 crore for Q2FY12 as compared to Rs 479.49 crore for Q2FY11.
The group has reported a consolidated net profit of Rs 127.58 crore for the quarter under teview on improved sales in all markets led by the US. The company had posted a net loss of Rs 96.68 crore for the corresponding quarter previous year.
Wockhardt USA reported a sales growth of 49% with its prime products improving market share in a highly competitive market scenario. There were three abbreviated new drug application (ANDA) filings and four approvals for the quarter, the company said.
The company's India business grew by 13.5% in the second quarter this fiscal, capturing a market share of 2.03% as compared to 1.94% last year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1842.30 |
| Dr. Reddys Lab | 1278.10 |
| Cipla | 1336.80 |
| Zydus Lifesciences | 932.30 |
| Lupin | 2273.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: